keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/28317397/nucleos-t-ide-analogues-for-preventing-hbv-reactivation-in-immunosuppressed-patients-with-hematological-malignancies-a-network-meta-analysis
#1
Min-Yue Zhang, Gui-Qi Zhu, Ji-Na Zheng, Zhang Cheng, Sven Van Poucke, Ke-Qing Shi, Hong-Hui Huang, Fang-Yuan Chen, Ming-Hua Zheng
Abstracts Background: We aimed to evaluate the efficacy of five oral nucleos(t)ide analogues (NAs), including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of hepatitis B virus (HBV) reactivation and HBV-related complications in chronic hepatitis B virus (CHB) infected patients with hematological malignancies receiving chemotherapy or hematopoietic stem cell transplantation (HSCT) by network meta-analysis. METHODS: The search identified 28 articles involving 5 different prophylactic regimens covering 1478 participants...
March 20, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28314596/on-treatment-hbv-dna-level-could-predict-hbeag-seroclearance-in-patients-with-hbeag-positive-chronic-hepatitis-b-with-entecavir-therapy
#2
Yi-Jie Huang, Chi-Sen Chang, Yen-Chun Peng, Hong-Zen Yeh, Sheng-Shun Yang
BACKGROUND: Hepatitis B e antigen (HBeAg) status is associated with clinical outcomes, and seroconversion of HBeAg is one of the treatment goals. In this study, we determined the association of on-treatment serum hepatitis B virus (HBV) DNA levels in HBeAg-positive chronic hepatitis B patients who were receiving entecavir (ETV) treatment. METHODS: A retrospective cohort study was conducted involving 135 (78 male and 57 female; mean age, 42.3 ± 13 years) patients with HBeAg-positive chronic hepatitis B (CHB)...
March 14, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28304106/therapeutic-plasma-exchange-versus-double-plasma-molecular-absorption-system-in-hepatitis-b-virus-infected-acute-on-chronic-liver-failure-treated-by-entercavir-a-prospective-study
#3
Yue-Meng Wan, Yu-Hua Li, Zhi-Yuan Xu, Jing Yang, Li-Hong Yang, Ying Xu, Jin-Hui Yang
BACKGROUND: Therapeutic plasma exchange (TPE) and double plasma molecular absorption system (DPMAS) were two extracorporeal liver support systems. Few studies compared their efficacy profile. OBJECTIVE: This study was to compare the efficacy of TPE and DPMAS on acute-on-chronic liver failure (ACLF) caused by hepatitis B virus (HBV-ACLF). METHODS: 60 HBV-ACLF patients were enrolled and prospectively studied. All patients received entecavir therapy, and were assigned to TPE group (n = 33) and DPMAS group (n = 27)...
March 17, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28282964/serum-hepatitis-b-core-related-antigen-is-a-satisfactory-surrogate-marker-of-intrahepatic-covalently-closed-circular-dna-in-chronic-hepatitis-b
#4
En-Qiang Chen, Shu Feng, Meng-Lan Wang, Ling-Bo Liang, Ling-Yun Zhou, Ling-Yao Du, Li-Bo Yan, Chuan-Min Tao, Hong Tang
Recently, hepatitis B core-related antigen (HBcrAg) has been suggested as an additional marker of hepatitis B virus (HBV) infection. This study aimed to investigate whether serum quantitative HBcrAg (qHBcrAg) was a satisfactory surrogate marker of intrahepatic covalently closed circular DNA (cccDNA). A total of 139 patients with liver biopsy were enrolled, consisting of 59 patients in immune tolerance (IT) phase, 52 patients in immune clearance (IC) phase, 18 patients in low-replication (LR) phase, and 10 patients in reactivation phase...
December 2017: Scientific Reports
https://www.readbyqxmd.com/read/28279168/comparison-of-the-long-term-efficacy-between-entecavir-and-tenofovir-in-treatment-na%C3%A3-ve-chronic-hepatitis-b-patients
#5
COMPARATIVE STUDY
Ji Won Park, Kyeong Min Kwak, Sung Eun Kim, Myoung Kuk Jang, Ki Tae Suk, Dong Joon Kim, Sang Hoon Park, Myung Seok Lee, Hyoung Su Kim, Choong Kee Park
BACKGROUND: There have been limited studies directly comparing the long-term efficacy between entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study was aimed to compare the long-term efficacy between them in treatment-naïve chronic hepatitis B (CHB). METHODS: Out of 345 CHB patients who received first line therapy with ETV (n = 200) or TDF (n = 145) in a cohort, 210 patients were analyzed using propensity score matching, at a ratio of 1:1...
March 9, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28274240/effect-of-48-week-pegylated-interferon-%C3%AE-2a-or-nucleos-t-ide-analogue-therapy-on-renal-function-in-chinese-patients-with-chronic-hepatitis-b
#6
Ye Zhang, Wei-Lu Zhang, Xiao-Wen Pang, Lin-Xu Wang, Xin Wei, Chang-Xing Huang, Xue-Fan Bai, Shuai Han, Lin-Na Liu, Jian-Qi Lian
BACKGROUND: Controversy remains as to whether antiviral agents contribute to renal dysfunction in patients with chronic hepatitis B virus (HBV) infection. Thus, the aim of study was to analyze the changes in renal function of chronic hepatitis B (CHB) patients in response to anti-HBV therapy and the association with treatments. METHOD: We performed a retrospective observational cohort study to investigate factors associated with renal function in 249 Chinese CHB patients who were treated with pegylated interferon α-2a (PEG-IFN-α-2a) or nucleos(t)ide analogues for 48 weeks...
March 9, 2017: Virology Journal
https://www.readbyqxmd.com/read/28273209/influence-of-treg-cells-and-hbv-genotype-on-sustained-response-and-drug-resistance-in-the-treatment-with-nucleoside-drugs
#7
Y R Zhang, B Li, C X Wang, N Zhou, W Qi, X L Li, L Y Wu, S F Wei, Y D Zhang
We aimed to investigate the influence of regulatory T cells including CD4+CD25+, CD8+CD28- and hepatitis B virus (HBV) genotype on sustained virological response and tolerance of nucleoside drugs. One hundred and thirty-seven patients were enrolled. Lamivudine was administered to 84 patients. Entecavir was administered to the other 53 patients. Before treatment, biochemical tests, HBV DNA load, HBV serum level, HBV genotype, PB CD3+, CD4+, CD8+, CD4+CD25+/CD3+, and CD8+CD28-/CD3+ frequencies were measured. Based on HBV DNA loads after 4 weeks of therapy, patients were divided into response group and suboptimal response group...
March 2, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/28270871/antiviral-therapy-in-chronic-hepatitis-b-with-mild-acute-exacerbation
#8
Su Lin, Qiaoxia Ye, Mingfang Wang, Yinlian Wu, Zhiyuan Weng, Yueyong Zhu
BACKGROUND: The aim of this study was to assess the efficacy and safety of peginterferon α-2a (pegIFN) and nucleos(t)ide analogues (NA) treatments in patients with hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B (CHB) with mild acute exacerbation (AE). METHODS: Treatment-naive HBeAg-positive CHB patients with AE who received pegIFN or NA (entecavir (ETV) or telbivudine (LDT)) therapies were retrospectively selected. The HBeAg seroconversion rate, hepatitis B surface antigen (HBsAg) loss rate and the cost-effectiveness of different treatments were compared...
February 2017: Gastroenterology Research
https://www.readbyqxmd.com/read/28261380/adverse-effects-of-oral-antiviral-therapy-in-chronic-hepatitis-b
#9
REVIEW
Bircan Kayaaslan, Rahmet Guner
Oral nucleoside/nucleotide analogues (NAs) are currently the backbone of chronic hepatitis B (CHB) infection treatment. They are generally well-tolerated by patients and safe to use. To date, a significant number of patients have been treated with NAs. Safety data has accumulated over the years. The aim of this article is to review and update the adverse effects of oral NAs. NAs can cause class adverse effects (i.e., myopathy, neuropathy, lactic acidosis) and dissimilar adverse effects. All NAs carry a "Black Box" warning because of the potential risk for mitochondrial dysfunction...
February 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28251118/optimizing-antiviral-agents-for-hepatitis-b-management-in-malignant-lymphomas
#10
REVIEW
Oluwatobi O Ozoya, Julio Chavez, Lubomir Sokol, Samir Dalia
The global scale of hepatitis B infection is well known but its impact is still being understood. Missed hepatitis B infection impacts lymphoma therapy especially increased risk of hepatitis B virus (HBV) reactivation and poor treatment outcomes. The presence of undiagnosed chronic hepatitis also undermines chronic HBV screening methods that are based on a positive HBsAg alone. The goal of this review is to evaluate the literature for optimizing antiviral therapy for lymphoma patients with HBV infection or at risk of HBV reactivation...
February 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28251116/pediatric-hepatitis-b-treatment
#11
REVIEW
Haruki Komatsu, Ayano Inui, Tomoo Fujisawa
Although the introduction of hepatitis B vaccine has been contributing to the reduction in the prevalence of hepatitis B virus (HBV) carriers worldwide, the treatment of children with chronic HBV infection is a challenge to be addressed. HBeAg seroconversion, which induces low replication of HBV, is widely accepted as the first goal of antiviral treatment in children with chronic hepatitis B. However, spontaneous HBeAg seroconversion is highly expected in children with chronic HBV infection. Therefore, the identification of children who need antiviral treatment to induce HBeAg seroconversion is essential in the management of chronic HBV infection...
February 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28249574/reactivation-of-occult-hbv-infection-in-an-hiv-hcv-co-infected-patient-successfully-treated-with-sofosbuvir-ledipasvir-a-case-report-and-review-of-the-literature
#12
Gabriele Fabbri, Ilaria Mastrorosa, Alessandra Vergori, Valentina Mazzotta, Carmela Pinnetti, Susanna Grisetti, Mauro Zaccarelli, Adriana Ammassari, Andrea Antinori
BACKGROUND: Reactivation of occult or inactive Hepatitis B virus (HBV) infection during immunosuppressant treatments is well known and widely described in literature. The same observation has been made in Hepatitis C (HCV)-infected patients previously exposed to HBV and treated with interferon-free DAA treatments. Because of common transmission routes, persons may have been exposed to HCV, HBV and HIV, but few cases have been reported in this scenario to date. Frequency of HBV reactivation in HIV/HCV co-infected patients previously exposed to HBV and treated with DAA remains unclear...
March 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28243319/comparison-of-fib-4-index-and-aspartate-aminotransferase-to-platelet-ratio-index-on-carcinogenesis-in-chronic-hepatitis-b-treated-with-entecavir
#13
Hiroki Nishikawa, Norihiro Nishijima, Hirayuki Enomoto, Azusa Sakamoto, Akihiro Nasu, Hideyuki Komekado, Takashi Nishimura, Ryuichi Kita, Toru Kimura, Hiroko Iijima, Shuhei Nishiguchi, Yukio Osaki
AIMS: We sought to compare the effects of FIB-4 index and aspartate aminotransferase to platelet ratio index (APRI) on hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients undergoing entecavir (ETV) therapy. PATIENT AND METHODS: A total of 338 nucleosides analogue therapy naïve CHB patients initially treated with ETV were analyzed. The optimal cutoff points in each continuous variable were determined by receiver operating curve (ROC) analysis...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28233741/lamivudine-entecavir-or-tenofovir-treatment-of-hepatitis-b-infection-effects-on-calcium-phosphate-fgf23-and-indicators-of-bone-metabolism
#14
Ramesh Saeedi, Ali Mojebi-Mogharar, Supna K Sandhu, Joshua A Dubland, Jo-Ann Ford, Masoud Yousefi, Morris Pudek, Daniel T Holmes, Siegfried R Erb, Wing Peter Kwan, David L Kendler, Eric M Yoshida
BACKGROUND: Patients with chronic hepatitis B virus (HBV) are often treated with nucleoside/nucleotide antiviral agents and metabolic bone toxicity is a possible concern. OBJECTIVE: To determine the relationships between fibroblast growth factor 23 (FGF23), a phosphaturic hormone, bone mineral density (BMD), and bone biochemical abnormalities in these patients. MATERIAL AND METHODS: This is a cross-sectional observational study comparing HBV-infected subjects treated for at least one year with tenofovir (TDF), lamuvidine (LVD), entacavir (ETV), or not treated (CON)...
March 1, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28230928/reactivation-of-hepatitis-b-in-patients-of-chronic-hepatitis-c-with-hepatitis-b-virus-infection-treated-with-direct-acting-antivirals
#15
Ming-Lun Yeh, Chung-Feng Huang, Meng-Hsuan Hsieh, Yu-Min Ko, Kuan-Yu Chen, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ching-I Huang, Jee-Fu Huang, Po-Lin Kuo, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang
BACKGROUND AND AIMS: Hepatitis B virus (HBV) may reactivate when treating chronic hepatitis C (CHC) with direct acting antivirals (DAA). We aim to investigate the risk of HBV reactivation during DAA therapy. METHODS: CHC patients receiving pan-oral DAA therapy from Dec. 2013 to Aug. 2016 were evaluated. Fifty-seven patients that had a past HBV infection (negative hepatitis B surface antigen (HBsAg)) and positive hepatitis B core antibody (Anti-HBc)) and 7 patients that had a current HBV infection (positive HBsAg) were enrolled...
February 23, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28220833/early-hepatitis-b-surface-antigen-decline-predicts-treatment-response-to-entecavir-in-patients-with-chronic-hepatitis-b
#16
Cheng-Yuan Peng, Hsueh-Chou Lai, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen, Ching-Hsiang Chen
Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving entecavir treatment remain unclear. We prospectively enrolled 529 patients (195 hepatitis B e antigen [HBeAg]-positive and 334 HBeAg-negative) with a median treatment duration of 49.2 months. Median HBsAg levels declined significantly in both groups at Month 3, but only at Months 6-12 in the HBeAg-negative group. Both groups exhibited a significant HBsAg decline with each successive year of treatment...
February 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28218868/-diagnosis-and-treatment-of-chronic-hepatitis-b-and-d-national-consensus-guideline-in-hungary-from-15-october-2016
#17
Gábor Horváth, Zsuzsanna Gerlei, Judit Gervain, Gabriella Lengyel, Mihály Makara, Alajos Pár, László Rókusz, Ferenc Szalay, István Tornai, Klára Werling, Béla Hunyady
Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0...
February 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28208002/expression-of-hepatocyte-hepatitis-b-core-antigen-and-hepatitis-b-surface-antigen-as-a-marker-in-the-management-of-chronic-hepatitis-b-patients
#18
Sun Young Yim, Tae Hyung Kim, Suh Sang Jun, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Hyung Joon Yim, Yoon Tae Jeen, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Nam Hee Won, Ho Sang Ryu
Background/Aims: We aimed to clarify the association of HBsAg/HBcAg with the disease status and treatment response in patients with chronic hepatitis B (CHB). Methods: We investigated 171 biopsy-proven entecavir-treated CHB patients (109 HBeAg-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous...
February 17, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28197805/economic-analysis-and-budget-impact-of-tenofovir-and-entecavir-in-the-first-line-treatment-of-hepatitis-b-virus-in-italy
#19
M Ruggeri, M Basile, S Coretti, C Drago, A Cicchetti
BACKGROUND: Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected. Oral antivirals can suppress viral replication and prevent or delay the development of cirrhosis and liver-related complications. The treatments of chronic hepatitis B cannot totally cure the disease but can prevent its progression to hepatocellular carcinoma, decreasing the levels of both morbidity and mortality. To date, there are several therapies indicated by the international guidelines as first-line treatments for the management of hepatitis B; two of the most effective are those based on either tenofovir or entecavir...
February 14, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28192212/anti-hbv-drugs-suppress-the-growth-of-hbv-related-hepatoma-cells-via-down-regulation-of-hepatitis-b-virus-x-protein
#20
Shuqin Zhang, Shan Gao, Man Zhao, Yunxia Liu, Yanan Bu, Qiulei Jiang, Qiang Zhao, Lihong Ye, Xiaodong Zhang
Chronic infection of hepatitis B virus (HBV) is closely associated with the development of hepatocellular carcinoma (HCC). Meta-analyses show that adjuvant anti-HBV therapy is effective for HBV-related HCC patients in clinical. However, the significance that anti-HBV drugs depress HCC is poorly understood. Here, we investigated the effects of telbivudine (LdT), entecavir (ETV) and interferon-α2b (IFN-α2b) on HBV-related HCC. Our data showed that the treatment with the drugs significantly suppressed the growth of HBV-expressing hepatoma cells in vitro and in vivo, but failed to work in HBV-free liver cells...
February 9, 2017: Cancer Letters
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"